$DTIL

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Co

Precision BioSciences presented Phase 1 data at AASLD 2026 showing its gene-editing therapy PBGENE-HBV eliminated hepatitis B viral reservoirs in 92% of target-dose patients. The study involved 25 patients, with 11 of 12 achieving undetectable pgRNA, a key biomarker. Precision plans to advance to a global Phase 2 study.

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.—November 5, 2026 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel p

Precision BioSciences priced a $125M offering of common stock and pre-funded warrants, expected to close Nov 6, 2026. Proceeds will fund R&D for PBGENE-HBV and PBGENE-DMD, and general corporate purposes. TD Cowen and Guggenheim Securities are joint book-running managers. According to the company, the offering is subject to customary closing conditions.

Precision BioSciences (DTIL) reported that the first patient in the FUNCTION-DMD trial completed an 8-week observation period with no safety concerns. The Data Safety Monitoring Board approved dosing additional patients. PBGENE-DMD, the company's gene-editing therapy for Duchenne muscular dystrophy, received FDA designations including Orphan Drug and Fast Track.

Precision BioSciences reported successful Phase 1 results for PBGENE-HBV, its hepatitis B treatment. The drug achieved undetectable pgRNA levels, reduced cccDNA, and showed a favorable safety profile at 0.4 mg/kg. The company plans to advance to a global Phase 2 study in 2027. Precision will host an investor webcast on November 9, 2026, to discuss the data.

Precision BioSciences (DTIL) reported Q3 EPS of -$0.28, beating estimates by $0.56, but revenue of $1.25M missed expectations. Stock is down 7.21% over 3 months, up 4.48% over 12 months. InvestingPro rates its financial health as 'fair performance'.

Precision Biosciences reported 3Q 2026 revenue of $0, down from $13K a year ago, and a net loss of $7.6M, improved from $21.8M. EPS was $(0.28). Nine-month revenue was $10.8M, driven by partnerships. Clinical trials for PBGENE-HBV, PBGENE-DMD, and other programs progressed.

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update - PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 - - Dos

Frankel Stanley purchased 1,000 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.00 on 2026-09-28.